Navigation Links
Renova Therapeutics co-founder awarded highest research honor by the U.S. Department of Veterans Affairs
Date:9/6/2017

SAN DIEGO, Sept. 6, 2017 /PRNewswire/ -- Renova™ Therapeutics, a biotechnology company developing gene and peptide-based treatments for cardiovascular and metabolic diseases, today announced that the company's co-founder Dr. H. Kirk Hammond is the recipient of the 2017 William S. Middleton Award, the highest biomedical laboratory research award in the U.S. Department of Veterans Affairs (VA).

Dr. H. Kirk Hammond, Co-founder of Renova Therapeutics, is a Professor of Medicine at UC San Diego and a cardiologist with the Veterans Affairs San Diego Healthcare System.
Dr. H. Kirk Hammond, Co-founder of Renova Therapeutics, is a Professor of Medicine at UC San Diego and a cardiologist with the Veterans Affairs San Diego Healthcare System.

The Middleton Award is given annually to recognize outstanding achievements in biomedical research. Dr. Hammond, a Professor of Medicine at UC San Diego and a cardiologist with the VA San Diego Healthcare System, received the award for his contributions to the understanding of mechanisms of cardiovascular disease and novel gene transfer treatments for angina and heart failure. Dr. Hammond is also investigating gene transfer for type 2 diabetes.

Dr. Hammond has authored more than 100 peer-reviewed publications related to cardiovascular disease and is an inventor on nine patents. He devised and led the Phase 2 clinical trial of AC6 gene transfer for the treatment of patients with heart failure and reduced ejection fraction. Results of the trial indicated that, through a one-time administration, AC6 gene transfer safely increased heart function beyond optimal heart failure therapy (JAMA Cardiology). This study was funded by the National Institutes of Health (NIH), the Gene Therapy Resource Program and Renova Therapeutics, via an NIH public-private partnership.

"If successful, these trials could lead to the first registration of a gene therapy product for treating heart disease," said Dr. Rachel Ramoni, VA's Chief Research and Development Officer. "Dr. Hammond is clearly a pioneer of intracoronary gene therapy and novel patient delivery mechanisms that will have a broad impact on the health care of veterans."

AC6 gene transfer is being developed by Renova Therapeutics as RT-100, its lead gene therapy candidate advancing to a Phase 3 clinical trial known as FLOURISH.

About heart failure
Heart failure is a chronic disease characterized by the inability of the heart to pump sufficient blood to meet the body's demands. It is a progressive and fatal chronic condition, and symptoms worsen over time. Heart failure afflicts more than 28 million people globally and is the only cardiovascular disease that is increasing in prevalence. In the United States, it is the most common cause for emergency hospital admissions in patients 65 and older.

About Renova Therapeutics
Renova Therapeutics is developing definitive, one-time gene therapies and peptide infusion treatments to restore the health of people suffering from chronic diseases. The first indications the company is pursuing are gene therapy treatments for heart failure and type 2 diabetes, two of the most common and devastating chronic diseases in the world. The company's lead product, RT-100, is a treatment that delivers a therapeutic gene directly to the heart during a routine outpatient procedure and has the potential to increase heart function in millions of patients with heart failure. The company's product pipeline also includes a groundbreaking gene therapy in preclinical stage for sufferers of type 2 diabetes, as well as a peptide infusion therapy for the treatment of acute decompensated heart failure. Renova Therapeutics was founded in 2009 and is led by an experienced management team in biopharmaceuticals and gene therapy. For additional information about the company, please visit www.renovatherapeutics.com.

References

  • Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics–2013 update: a report from the American Heart Association. Circulation. 2013;127:e6–e245.

View original content with multimedia:http://www.prnewswire.com/news-releases/renova-therapeutics-co-founder-awarded-highest-research-honor-by-the-us-department-of-veterans-affairs-300514250.html


'/>"/>
SOURCE Renova Therapeutics
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Don't miss the I2SL High-Tech Talks Webinar Series Presenting: Butler University's Renovation With Filtered Fume Hoods, 3 Years Later
2. RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate
3. Temarry Recycling’s New $100,000 Waste to Energy Renovation
4. Renova Therapeutics expands clinical development team with latest hire
5. Biotech finance expert joins Renova Therapeutics as CFO
6. Renova Therapeutics secures novel AAV vector license for use in metabolic and cardiovascular gene therapy development
7. UNIAPAC Foundation Think Tank in Paris selects Renova Therapeutics CEO and Co-founder as keynote speaker for annual meeting
8. Industry leaders join Renova Therapeutics to lead preclinical programs into clinical development
9. Peptide Therapeutics Market is Expected to Reach USD 25.4 Billion Globally in 2018: Transparency Market Research
10. Novira Therapeutics Completes $25 Million Series A Financing
11. Biovista und DART Therapeutics nehmen Zusammenarbeit auf, um auf Duchenne-Muskeldystrophie abzielende Medikamente neu zu positionieren
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/19/2020)... ... 2020 , ... Family counsellors, marriage/couples therapists, and those interested ... their perceptions of events. Imagine if a couple’s counsellor could see the impact ... the level of engagement of each individual in the therapeutic process, then tailor ...
(Date:3/10/2020)... ... March 10, 2020 , ... ... cold chain biopharmaceutical engineering firm, is pleased to announce the addition of ... combination medical device qualification and validation in the biopharmaceutical cold chain. He ...
(Date:3/3/2020)... ... March 03, 2020 , ... Frictionless Solutions, a ... device industries, was recognized by INC. 5,000 on an annual list of America’s ... industry leaders greatly impacting their spheres of influence and experiencing considerable development. INC. ...
(Date:2/26/2020)... ... February 25, 2020 , ... Continuing its leading research ... results of its safety assessment on the biotechnologically produced 3-Fucolsyllactose (3-FL) HMO. ... These complex carbohydrates are indigestible and therefore function as a prebiotic by promoting ...
Breaking Biology Technology:
(Date:3/27/2020)... ... March 25, 2020 , ... ixlayer, an ... address the need to rapidly launch and scale COVID-19 clinical testing. The ixlayer ... deliver, has been adapted for COVID-19 specific content and user flows, allowing physicians/health ...
(Date:3/20/2020)... Conn. (PRWEB) , ... March 20, 2020 , ... ... the development of human embryonic stem cell (ESC) derived mesenchymal stem cells (hES-MSC), ... T-MSC) for the treatment of neurological, autoimmune, and rare orphan diseases, today announced ...
(Date:3/19/2020)... ... ... The former Jason "Furious" Styles of "Boyz n the Hood" (1991), Laurence ... TV program highlights a large variety of subjects that have an impact on a ... dive into the world of applied academics. The episode will cover education in biomechanical ...
Breaking Biology News(10 mins):